Results 321 to 330 of about 3,932,256 (404)

A cross-sectional analysis on hypertension: Exploring the impact of lifestyle modifications and antihypertensive drug adherence in Sudan. [PDF]

ARYA Atheroscler
Ahmed A, Rikabi HA, Soomro S, Em AE, Estabrag SH, Elham A A.   +5 more
europepmc   +1 more source

Investigating multimorbidity trajectories in people living with MASLD diagnosis: A trajectory analysis using the UK Biobank

Diabetes, Obesity and Metabolism, EarlyView.
Abstract Background Metabolic dysfunction‐associated steatotic liver disease (MASLD) is an emerging global health concern, and its presence increases the risk of multi‐system diseases. This study aimed to investigate the multimorbidity trajectories of chronic diseases in people living with MASLD.
Fang Lu, Hailin Yang, Bingyang She, Qianhui Lu, Yining Bao, Wai‐Kay Seto, William C. W. Wong, Man‐Fung Yuen, Yingli He, Xinyuan He, Fanpu Ji, Lei Zhang   +11 more
wiley   +1 more source

Antihypertensive drug concentration measurement combined with personalized feedback in resistant hypertension: a randomized controlled trial. [PDF]

J Hypertens
Peeters LEJ, Kappers MHW, Hesselink DA, van der Net JB, Hartong SCC, van de Laar R, Ezzahti M, van de Ven PJG, van der Meer IM, de Bruijne ELE, Kroon AA, Indhirajanti-Tomasoa S, van der Linde NAJ, Bahmany S, Boersma E, Massey EK, van Dijk L, van Gelder T, Koch BCP, Versmissen J.   +19 more
europepmc   +1 more source

Tirzepatide and the 10‐year predicted risk of cardiovascular disease and type 2 diabetes in adults with obesity and prediabetes: A post hoc analysis from the three‐year SURMOUNT‐1 trial

Diabetes, Obesity and Metabolism, EarlyView.
Abstract Aim We assessed the association between tirzepatide and the 10‐year predicted risk of developing cardiovascular disease (CVD) and type 2 diabetes (T2D) among three‐year SURMOUNT‐1 trial participants. Materials and Methods This post hoc analysis applied validated risk engines that predict 10‐year CVD (atherosclerotic cardiovascular disease ...
Emily R. Hankosky, Jeremie Lebrec, Clare J. Lee, Georgios K. Dimitriadis, Irina Jouravskaya, Adam Stefanski, W. Timothy Garvey   +6 more
wiley   +1 more source

Plasma sphingolipids predict advanced liver fibrosis development in patients with type 2 diabetes

Diabetes, Obesity and Metabolism, EarlyView.
Abstract Aims Patients with type 2 diabetes (T2D) are at an elevated risk of developing metabolic dysfunction‐associated steatotic liver disease (MASLD), with a significant likelihood of progression to advanced liver fibrosis (AF)—a stage linked to adverse outcomes.
Sarah Béland‐Bonenfant, Damien Denimal, Jean‐Paul Pais‐de‐Barros, Hélène Choubley, Alexia Rouland, Isabelle Simoneau, Laurence Duvillard, Ludwig‐Serge Aho‐Glélé, Benjamin Bouillet, Jean‐Michel Petit, Bruno Vergès   +10 more
wiley   +1 more source

Partial non‐adherence to antidiabetic therapy undermines diabetes management and correlates with treatment complexity: A cross‐sectional study using blood plasma analysis

Diabetes, Obesity and Metabolism, EarlyView.
Abstract Aims To evaluate medication adherence in patients with type 2 diabetes (T2D) using plasma drug measurements and assess the clinical impact of partial non‐adherence on glycemic control and complications. Materials and Methods This cross‐sectional study included 641 T2D outpatients attending routine follow‐up visits.
Vojtěch Škop, Ivana Laňková, Simona Antalová, Iva Míšková, Kateřina Malá‐Ládová, Josef Malý, Terezie Pelikánová, Jiří Hricko, Tomáš Čajka, Martin Haluzík   +9 more
wiley   +1 more source

Risk of depression with GLP‐1 receptor agonists use in overweight or obese adults with type 2 diabetes: A new‐user, active‐comparator cohort study

Diabetes, Obesity and Metabolism, EarlyView.
Abstract Aims The association between glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) and depression remains uncertain due to contradictory evidence. We compared the risk of incident depression between GLP‐1 RAs and sodium‐glucose cotransporter‐2 inhibitors (SGLT2is) in overweight or obese adults with type 2 diabetes.
Yu Chang, Ming‐Hong Hsieh, Po‐Chung Ju, Cheng‐Chen Chang   +3 more
wiley   +1 more source

Addressing unmet needs for chronic kidney disease treatment in type 1 diabetes: A review

Diabetes, Obesity and Metabolism, EarlyView.
Abstract Chronic kidney disease (CKD) is a serious complication occurring in nearly one of three people with type 1 diabetes (T1D). Major therapeutic advances have been made in the management of CKD for people with type 2 diabetes (T2D), thereby improving their kidney, cardiovascular, and survival outcomes.
Katherine R. Tuttle, Linong Ji, Chantal Mathieu, Jonathan Rosen   +3 more
wiley   +1 more source

Health Policy Newsletter March 2007 Vol. 20, No. 1 [PDF]

, 2008

core   +1 more source